NVO down a bit pre-market, ER not that bad

Novo Nordisk (NVO) beat Q2 2025 EPS expectations ($1.87 vs. $0.93 consensus) and met revenue forecasts ($11.92 billion), with 13% year-over-year growth. The company maintained strong full-year sales growth guidance of 13-21% at constant exchange rates, signaling confidence despite competitive pressures. However, Wegovy sales slightly missed expectations, and the stock has been under pressure from recent declines and market challenges.